Skip to main content
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mSphere
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Commentary | Therapeutics and Prevention

mSphere of Influence: Evolutionary Strategies To Sensitize Drug-Resistant Pathogens

Rebecca S. Shapiro
Rebecca S. Shapiro
aDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rebecca S. Shapiro
DOI: 10.1128/mSphere.00313-19
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Rebecca S. Shapiro studies antimicrobial resistance and genetic interaction networks. In this mSphere of Influence article, she reflects on how the papers “Bacterial evolution of antibiotic hypersensitivity” by Lázár et al. (V. Lázár, G. Pal Singh, R. Spohn, I. Nagy, et al., Mol Syst Biol 9:700, 2013, https://doi.org/10.1038/msb.2013.57) and “Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development” by L. Imamovic and M. O. A. Sommer (Sci Transl Med 5:204ra132, 2013, https://doi.org/10.1126/scitranslmed.3006609) impacted her thinking about multigene interaction effects on drug resistance.

The views expressed in this article do not necessarily reflect the views of the journal or of ASM.

COMMENTARY

Early in my postdoctoral training, I was influenced by two complementary articles on antimicrobial collateral sensitivity, which exploited an understanding of drug resistance adaptation to devise novel strategies to manage antibiotic resistance: “Bacterial evolution of antibiotic hypersensitivity” by Lázár et al., in Molecular Systems Biology (1), and “Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development” by Imamovic and Sommer, in Science Translational Medicine (2), both published in 2013. These two articles sought to characterize antibiotic drug resistance profiles in a simple bacterial model and, moreover, to decipher complex collateral sensitivity networks between diverse antibiotics. Collateral sensitivity describes a phenomenon where the evolution of resistance to one drug consequently confers increased susceptibility to another drug—a sort of evolutionary tradeoff. Both these articles identify key collateral sensitivities between antibiotic agents; for example, they find that evolution of resistance to the aminoglycoside class of antibiotics often comes at the expense of increased sensitivity to other classes of antibiotic drugs, including quinolones and β-lactams. These studies elegantly demonstrate how such evolutionary tradeoffs can be exploited to increase antibiotic sensitivities within bacterial populations. Further, they suggest that collateral sensitivities could ultimately be exploited to inform treatment with combinations of antibiotics, to slow or prevent the emergence of drug resistance, and to enhance therapeutic efficacy.

For this research, both studies took an experimental evolution approach to drive the evolution of antibiotic drug resistance in vitro. Using Escherichia coli as a simple bacterial model system, both groups of researchers evolved dozens of lineages of bacteria in the presence of fixed or increasing concentrations of >20 distinct antibiotic drugs. The resultant experimentally evolved antibiotic-resistant populations were then assayed for resistance to panels of antibiotic drugs to which they had not previously been exposed, in order to identify novel collateral sensitivities. Both groups identified several instances of bacteria acquiring resistance to one antibiotic resulting in increased susceptibility to other antibiotics. In particular, collateral sensitivity between aminoglycoside and β-lactam antibiotics was identified by both groups. Imamovic and Sommer further demonstrated that cycling between these two classes of antibiotic drugs actively selects against antibiotic-resistant bacteria and effectively eradicates drug resistance in vitro (2). Lázár et al. used whole-genome sequencing to identify mutations associated with aminoglycoside resistance and suggested a putative mechanism whereby mutations affecting the proton-motive force across the bacterial inner membrane render cells hypersensitive to other classes of antibiotics (1).

While neither of these papers was the first to describe the phenomenon of collateral sensitivity (first described by Szybalski and Bryson [3]), they were the first to study this phenomenon in bacteria on a large scale and map out collateral sensitivity networks across dozens of distinct antibiotic drugs. Since my own research focuses on both antimicrobial resistance and genetic interaction networks, these papers influenced my thinking in several ways. First, I study genetic mechanisms of antimicrobial resistance, and I was enthusiastic to see this novel research that exploited the relatively simple idea of evolutionary tradeoffs to drive sensitivity or hypersensitivity to specific antibiotic drugs. That such naturally occurring tradeoffs could be coopted by researchers, or perhaps even clinicians, to actively select against antibiotic resistance is a very appealing concept, particularly in light of the growing crisis of drug-resistant infections. Second, another focus of my research is microbial genetic interactions (4) and elucidating how epistatic interactions between two mutant gene products can influence resistance to antimicrobial agents. The research presented in these two papers used a chemical-genetic approach to dissect how specific resistance mutations influence resistance or susceptibility to antibiotic drugs. I see these two approaches as highly complementary: collateral sensitivity profiling uses chemical-genetics to identify mutations that render cells hypersensitive to drugs, while genetic-interaction screening can identify secondary mutations (which could point to putative drug targets), which can sensitize drug-resistant mutants. These papers prompted me to consider how integrating these two approaches can advance our understanding of antimicrobial resistance and reveal novel strategies to promote antimicrobial susceptibility.

Since these papers were published, many more studies have delved further into the phenomenon of collateral sensitivity in diverse bacterial organisms. Recent work has revealed that collateral sensitivity networks are conserved in clinical isolates of E. coli and are generally predictable, based on the genetic mechanism of resistance (5). Collateral sensitivities have also recently been reported upon treatment with antimicrobial peptides (6), as well as antimicrobial natural products (7). Further, collateral sensitivities have been identified for other clinically relevant bacterial pathogens, including Pseudomonas aeruginosa (8, 9), and Staphylococcus aureus (10). While collateral sensitivity has also been described in cancer cell lines, as well in animal models of cancer (11, 12), it has yet to be comprehensively studied in eukaryotic microorganisms, including fungal pathogens and eukaryotic parasites, for which antimicrobial treatment options are limited and antimicrobial resistance is a growing concern. As such studies on collateral sensitivity progress, I am eager to learn if the rational design of treatment regimens based on collateral sensitivity profiles will have bearing in the context of complex clinical infections, and what additional challenges will remain in applying the theory learned in this research in clinical settings.

ACKNOWLEDGMENTS

I would like to thank J. Hill for helpful discussions.

This work was supported by the Canadian Institutes of Health Research (CIHR) project grant 162195.

  • Copyright © 2019 Shapiro.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Lázár V,
    2. Pal Singh G,
    3. Spohn R,
    4. Nagy I,
    5. Horváth B,
    6. Hrtyan M,
    7. Busa-Fekete R,
    8. Bogos B,
    9. Méhi O,
    10. Csörgő B,
    11. Pósfai G,
    12. Fekete G,
    13. Szappanos B,
    14. Kégl B,
    15. Papp B,
    16. Pál C
    . 2013. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol 9:700. doi:10.1038/msb.2013.57.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Imamovic L,
    2. Sommer M
    . 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med 5:204ra132. doi:10.1126/scitranslmed.3006609.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Szybalski W,
    2. Bryson V
    . 1952. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol 64:489–499.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Shapiro RS,
    2. Chavez A,
    3. Porter CBM,
    4. Hamblin M,
    5. Kaas CS,
    6. DiCarlo JE,
    7. Zeng G,
    8. Xu X,
    9. Revtovich AV,
    10. Kirienko NV,
    11. Wang Y,
    12. Church GM,
    13. Collins JJ
    . 2018. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans. Nat Microbiol 3:73–82. doi:10.1038/s41564-017-0043-0.
    OpenUrlCrossRef
  5. 5.↵
    1. Podnecky NL,
    2. Fredheim EGA,
    3. Kloos J,
    4. Sørum V,
    5. Primicerio R,
    6. Roberts AP,
    7. Rozen DE,
    8. Samuelsen Ø,
    9. Johnsen PJ
    . 2018. Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli. Nat Commun 9:3673. doi:10.1038/s41467-018-06143-y.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lázár V,
    2. Martins A,
    3. Spohn R,
    4. Daruka L,
    5. Grézal G,
    6. Fekete G,
    7. Számel M,
    8. Jangir PK,
    9. Kintses B,
    10. Csörgő B,
    11. Nyerges Á,
    12. Györkei Á,
    13. Kincses A,
    14. Dér A,
    15. Walter FR,
    16. Deli MA,
    17. Urbán E,
    18. Hegedűs Z,
    19. Olajos G,
    20. Méhi O,
    21. Bálint B,
    22. Nagy I,
    23. Martinek TA,
    24. Papp B,
    25. Pál C
    . 2018. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat Microbiol 3:718–731. doi:10.1038/s41564-018-0164-0.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Colclough A,
    2. Corander J,
    3. Sheppard SK,
    4. Bayliss SC,
    5. Vos M
    . 2019. Patterns of cross-resistance and collateral sensitivity between clinical antibiotics and natural antimicrobials. Evol Appl 12:878–887. doi:10.1111/eva.12762.
    OpenUrlCrossRef
  8. 8.↵
    1. Imamovic L,
    2. Ellabaan MMH,
    3. Dantas Machado AM,
    4. Citterio L,
    5. Wulff T,
    6. Molin S,
    7. Krogh Johansen H,
    8. Sommer M
    . 2018. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell 172:121–134.e14. doi:10.1016/j.cell.2017.12.012.
    OpenUrlCrossRef
  9. 9.↵
    1. Barbosa C,
    2. Beardmore R,
    3. Schulenburg H,
    4. Jansen G
    . 2018. Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model. PLoS Biol 16:e2004356. doi:10.1371/journal.pbio.2004356.
    OpenUrlCrossRef
  10. 10.↵
    1. Kim S,
    2. Lieberman TD,
    3. Kishony R
    . 2014. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A 111:14494–14499. doi:10.1073/pnas.1409800111.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Zhao B,
    2. Sedlak JC,
    3. Srinivas R,
    4. Creixell P,
    5. Pritchard JR,
    6. Tidor B,
    7. Lauffenburger DA,
    8. Hemann MT
    . 2016. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165:234–246. doi:10.1016/j.cell.2016.01.045.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Hall MD,
    2. Handley MD,
    3. Gottesman MM
    . 2009. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30:546–556. doi:10.1016/j.tips.2009.07.003.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
mSphere of Influence: Evolutionary Strategies To Sensitize Drug-Resistant Pathogens
Rebecca S. Shapiro
mSphere Jun 2019, 4 (3) e00313-19; DOI: 10.1128/mSphere.00313-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mSphere article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
mSphere of Influence: Evolutionary Strategies To Sensitize Drug-Resistant Pathogens
(Your Name) has forwarded a page to you from mSphere
(Your Name) thought you would be interested in this article in mSphere.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
mSphere of Influence: Evolutionary Strategies To Sensitize Drug-Resistant Pathogens
Rebecca S. Shapiro
mSphere Jun 2019, 4 (3) e00313-19; DOI: 10.1128/mSphere.00313-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • COMMENTARY
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

antibiotics
antimicrobial drug resistance
collateral sensitivity
experimental evolution
microbial pathogens

Related Articles

Cited By...

About

  • About mSphere
  • Board of Editors
  • Policies
  • For Reviewers
  • For the Media
  • Embargo Policy
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Types of Articles
  • Getting Started
  • Ethics
  • Contact Us

Follow #mSphereJ

@ASMicrobiology

       

 

Website feedback

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2379-5042